Priority Health Expands GRAIL's Galleri Test to Michigan Employer Plans
Event summary
- GRAIL partners with Priority Health to offer the Galleri multi-cancer early detection test to self-insured employer groups in Michigan.
- Priority Health previously launched coverage for Galleri in its Medicare Advantage plans in 2025.
- Galleri screens for over 50 cancer types, including those without recommended screening tests like pancreatic and ovarian cancers.
- The test has demonstrated a reduction in Stage IV diagnoses by more than 20% after the first year of screening.
The big picture
This collaboration marks a significant step in the adoption of multi-cancer early detection tests within employer-sponsored health plans. Priority Health, serving over 1.4 million members, provides GRAIL with a substantial platform to demonstrate Galleri's value in reducing late-stage cancer diagnoses and associated healthcare costs. The expansion into employer plans follows successful integration into Medicare Advantage, signaling growing acceptance of MCED tests as part of standard care.
What we're watching
- Market Adoption
- How quickly other health plans will follow Priority Health in offering Galleri to employer groups.
- Clinical Impact
- Whether the test's performance in real-world settings matches its clinical trial results.
- Regulatory Dynamics
- The pace at which regulatory approvals may expand Galleri's availability beyond current indications.
Related topics